← Back to Search

Monoclonal Antibodies

Brigatinib + Bevacizumab for Lung Cancer

Phase 1
Waitlist Available
Led By Victoria M. Villaflor, M.D.
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must have shown progression on ALK-directed therapy
Patients must have adequate organ and bone marrow function during screening
Must not have
Patients who have had major surgery within 30 days of registration, are not eligible
Patients with recent history of pulmonary embolism, or untreated deep vein thrombosis in the last 3 months are not eligible
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights

Summary

This trial tests brigatinib and bevacizumab in patients with a specific type of lung cancer that has spread or come back. Brigatinib blocks growth signals in cancer cells, while bevacizumab blocks the tumor's blood supply. The goal is to find the best dose and see how well these drugs work together.

Who is the study for?
This trial is for adults with ALK-rearranged non-small cell lung cancer that's advanced, spread elsewhere, or returned after treatment. They must have tried ALK-targeted therapy before and still show signs of the disease. Participants need to be in fairly good health overall, understand the study, agree to use contraception, and not have had certain treatments or surgeries recently.
What is being tested?
Researchers are testing brigatinib combined with bevacizumab to see how well they work together against this type of lung cancer. Brigatinib targets enzymes needed by cancer cells to grow while bevacizumab aims to stop these cells from spreading.
What are the potential side effects?
Possible side effects include high blood pressure, bleeding problems, fatigue, liver issues and risks related to heart health. There might also be reactions where the drugs are infused into the body and potential harm if a participant has surgery during the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer progressed despite treatment targeting ALK.
Select...
My organs and bone marrow are functioning well.
Select...
I have brain metastases but no symptoms, and I don't have cancer in the lining of my brain.
Select...
My lung cancer is advanced, recurrent, or has spread and tests show ALK changes.
Select...
I am following the required birth control guidelines.
Select...
I can take care of myself and am up and about more than half of my waking hours.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not had major surgery in the last 30 days.
Select...
I have not had a recent pulmonary embolism or untreated deep vein thrombosis in the last 3 months.
Select...
I don't have any other cancers that are likely to worsen within a year.
Select...
I do not have uncontrolled heart problems.
Select...
I do not have severe lung inflammation from drugs or radiation.
Select...
My blood pressure is under control.
Select...
I do not have severe unresolved lung disease.
Select...
I do not have any uncontrolled illnesses.
Select...
I am not pregnant, planning to become pregnant, or nursing.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of adverse events
Maximum tolerated dose
Secondary study objectives
Dose-limiting toxicities
Duration of response
Overall response rate
+2 more

Side effects data

From 2021 Phase 3 trial • 275 Patients • NCT02737501
57%
Diarrhoea
50%
Blood Creatine Phosphokinase Increased
36%
Cough
32%
Hypertension
32%
Nausea
26%
Back Pain
26%
Aspartate Aminotransferase Increased
23%
Headache
23%
Dyspnoea
23%
Alanine Aminotransferase Increased
23%
Lipase Increased
22%
Vomiting
21%
Fatigue
21%
Pruritus
20%
Arthralgia
19%
Constipation
18%
Rash
17%
Dizziness
15%
Muscle Spasms
15%
Pyrexia
13%
Upper Respiratory Tract Infection
13%
Abdominal Pain
13%
Blood Alkaline Phosphatase Increased
13%
Asthenia
12%
Decreased Appetite
11%
Dyspepsia
11%
Musculoskeletal Pain
10%
Insomnia
10%
Dermatitis Acneiform
10%
Myalgia
10%
Oedema Peripheral
10%
Blood Cholesterol Increased
10%
Oropharyngeal Pain
9%
Productive Cough
9%
Nasopharyngitis
9%
Anaemia
9%
Paraesthesia
9%
Stomatitis
9%
Musculoskeletal Chest Pain
8%
Non-Cardiac Chest Pain
8%
Abdominal Pain Upper
7%
Urinary Tract Infection
7%
Bradycardia
7%
Epistaxis
7%
Pneumonia
7%
Pain In Extremity
7%
Rash Erythematous
6%
Dry Skin
6%
Rash Maculo-Papular
6%
Dysphonia
6%
Electrocardiogram Qt Prolonged
6%
Dry Mouth
6%
Eczema
6%
Blood Creatinine Increased
5%
Sinus Bradycardia
5%
Respiratory Tract Infection
5%
Hyperglycaemia
5%
Hypokalaemia
5%
Hypercholesterolaemia
5%
Vision Blurred
5%
Blood Lactate Dehydrogenase Increased
5%
Hypophosphataemia
5%
Rhinorrhoea
5%
Malaise
4%
Depression
4%
Dysgeusia
4%
Influenza Like Illness
4%
Peripheral Swelling
4%
Gamma-Glutamyltransferase Increased
4%
Neoplasm Progression
2%
Neutrophil Count Decreased
2%
Pulmonary Embolism
2%
Pleural Effusion
2%
Interstitial Lung Disease
2%
Hypocalcaemia
2%
Hypoaesthesia
2%
Taste Disorder
2%
Hypotension
1%
Toxicity To Various Agents
1%
Lower Respiratory Tract Infection
1%
Appendicitis
1%
Gastroenteritis
1%
Visual Impairment
1%
Disseminated Intravascular Coagulation
1%
Confusional State
1%
Cerebrovascular Accident
1%
Dysarthria
1%
Encephalopathy
1%
Peripheral Sensory Neuropathy
1%
Cholestasis
1%
Muscular Weakness
1%
Malignant Pleural Effusion
1%
Cancer Pain
1%
Diffuse Large B-Cell Lymphoma
1%
Invasive Breast Carcinoma
1%
Lung Neoplasm Malignant
1%
Ovarian Cancer Stage I
1%
Neutropenia
1%
Gout
1%
Syncope
1%
Seizure
1%
Memory Impairment
1%
Vocal Cord Paralysis
1%
Pericardial Effusion
1%
Cardiac Tamponade
1%
Acute Myocardial Infarction
1%
Angina Pectoris
1%
Arrhythmia
1%
Pneumonitis
1%
Pneumonia Aspiration
1%
Pneumothorax
1%
Pulmonary Oedema
1%
Dysphagia
1%
Inguinal Hernia
1%
Neutropenic Colitis
1%
Oesophageal Obstruction
1%
Cholecystitis
1%
Bile Duct Stone
1%
Multiple Organ Dysfunction Syndrome
1%
Sudden Death
1%
C-Reactive Protein Increased
1%
Transaminases Abnormal
1%
Femoral Neck Fracture
1%
Fall
1%
Ligament Rupture
1%
Hypoalbuminaemia
1%
Viral Infection
1%
Metastases To Meninges
1%
Lung Adenocarcinoma
1%
Squamous Cell Carcinoma Of Skin
1%
Hypoglycaemia
1%
Delirium
1%
Balance Disorder
1%
Partial Seizures
1%
Atrial Fibrillation
1%
Hepatocellular Injury
1%
Acute Kidney Injury
1%
Photopsia
1%
Metastases To Central Nervous System
1%
Hyperkalaemia
1%
Cognitive Disorder
1%
Gastric Haemorrhage
1%
Mucosal Inflammation
1%
Gastrooesophageal Reflux Disease
1%
Respiratory Distress
100%
80%
60%
40%
20%
0%
Study treatment Arm
Randomized Phase: Brigatinib 90 mg QD/180 QD
Randomized Phase: Crizotinib 250 mg BID
Crossover Phase: Brigatinib 90 mg QD/180 mg QD

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (brigatinib, bevacizumab)Experimental Treatment2 Interventions
Patients receive brigatinib PO QD on days 1-28 of cycle 1 and days 1-21 of subsequent cycles. Patients also receive bevacizumab IV on day 8 of cycle 1 and day 1 of subsequent cycles. Starting cycle 2, cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bevacizumab
2013
Completed Phase 4
~5540
Brigatinib
2019
Completed Phase 3
~1140

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
ALK inhibitors like Brigatinib block the activity of the ALK protein, reducing tumor growth in ALK-rearranged NSCLC. Angiogenesis inhibitors like Bevacizumab inhibit VEGF, preventing the formation of new blood vessels that tumors need to grow. These targeted therapies are crucial for effectively treating lung cancer by addressing specific mechanisms that drive tumor growth and spread.
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer.Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future.

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,629 Previous Clinical Trials
958,185 Total Patients Enrolled
City of Hope Medical CenterLead Sponsor
596 Previous Clinical Trials
1,923,432 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,868 Previous Clinical Trials
41,010,832 Total Patients Enrolled

Media Library

Bevacizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04227028 — Phase 1
Lung Cancer Research Study Groups: Treatment (brigatinib, bevacizumab)
Lung Cancer Clinical Trial 2023: Bevacizumab Highlights & Side Effects. Trial Name: NCT04227028 — Phase 1
Bevacizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04227028 — Phase 1
~0 spots leftby Nov 2024